Table 1.
Summary of demographic, serological and vaccination status of participants
| Factor | Levels | N (%) |
|---|---|---|
| Age | <5 years | 41 (11.7%) |
| 5–17 years | 153 (43.8%) | |
| 18–49 years | 130 (37.2%) | |
| ≥50 years | 25 (7.2%) | |
| Sex | Female | 201 (57.6%) |
| Male | 148 (42.4%) | |
| Anti-spike antibody positivitya | V1 (n = 348) | 196 (56.3%) |
| V2 (n = 298) | 251 (84.2%) | |
| V3 (n = 268) | 254 (94.8%) | |
| Anti-nucleocapsid antibody positivitya | V1 (n = 348) | 165 (47.4%) |
| V2 (n = 298) | 206 (69.1%) | |
| V3 (n = 268) | 237 (88.4%) | |
| Vaccinated at 6 months (V2) | Yes | 32 (9.2%) |
| Vaccinated at 12 months (V3) | Yes | 48 (13.8%) |
| Household size, median (IQR) | – | 7 (6–10) |
| Number of rooms, median (IQR) | – | 7 (4–8) |
N = 349 unless otherwise stated.
aSpike and nucleocapsid antibody tested in participants who attended V1 (baseline), V2 (6-month), and V3 (12-month) visits and provided blood samples (number tested shown). No participants had been vaccinated against SARS-CoV-2 at study entry (V1).